Regulatory considerations for manufacturing, packaging and labeling in EU MCQs With Answer

Introduction:

This quiz set focuses on regulatory considerations for manufacturing, packaging and labeling of medicinal products within the European Union, tailored for M.Pharm students studying Regulatory Aspects of Drugs & Cosmetics (MRA201T). It emphasizes EU-specific legislative frameworks such as EudraLex Volume 4 (GMP), the Falsified Medicines Directive (FMD) and the role of the Qualified Person (QP). Questions address site authorisation, batch release, serialization and safety features, packaging material controls, labeling requirements (SmPC, PIL), and special requirements for sterile and temperature-sensitive products. The goal is to reinforce understanding of practical compliance expectations and how regulatory requirements influence day-to-day pharmaceutical operations in the EU.

Q1. What is the primary EU legal framework that sets out Good Manufacturing Practice requirements for medicinal products?

• EudraLex Volume 4
• ICH Q7 Guidance
• EU Clinical Trials Regulation
• Falsified Medicines Directive

Correct Answer: EudraLex Volume 4

Q2. Which EU role is legally responsible for certifying that each batch of medicinal product has been manufactured and checked in accordance with laws and marketing authorization before release?

• Qualified Person (QP)
• Responsible Pharmacist
• Manufacturing Manager
• Regulatory Affairs Officer

Correct Answer: Qualified Person (QP)

Q3. Which EU requirement mandates the placement of a unique identifier (2D barcode) and an anti-tampering device on the outer packaging of prescription medicines to prevent falsification?

• Falsified Medicines Directive (FMD) and Delegated Regulation
• Annex 1 of EudraLex Volume 4
• GDP Guidelines
• Clinical Trial Directive

Correct Answer: Falsified Medicines Directive (FMD) and Delegated Regulation

Q4. Which EudraLex annex provides specific updated guidance on manufacture of sterile medicinal products?

• Annex 1
• Annex 11
• Annex 15
• Annex 16

Correct Answer: Annex 1

Q5. For labeling a prescription-only medicinal product in the EU, which item is always required on the immediate pack?

• Batch number and expiry date
• Manufacturer’s profit margin
• Full clinical trial data
• Wholesale distributor name only

Correct Answer: Batch number and expiry date

Q6. Which document describes the authorised conditions of use, contraindications and posology and must be consistent with product labeling?

• Summary of Product Characteristics (SmPC)
• Good Distribution Practice (GDP)
• Manufacturing Authorisation
• Quality Risk Management Plan

Correct Answer: Summary of Product Characteristics (SmPC)

Q7. What is the principal purpose of packaging qualification and validation in pharmaceutical manufacturing?

• To ensure the packaging maintains product quality, identity and stability throughout shelf life
• To reduce packaging costs irrespective of performance
• To create attractive marketing designs only
• To increase batch sizes beyond validated limits

Correct Answer: To ensure the packaging maintains product quality, identity and stability throughout shelf life

Q8. Which EU requirement covers responsibilities for storage, transportation and traceability of medicinal products after manufacture?

• Good Distribution Practice (GDP)
• Annex 1
• Pharmacovigilance Risk Assessment Committee (PRAC) guidance
• Clinical Trial Regulation

Correct Answer: Good Distribution Practice (GDP)

Q9. Which of the following is a mandatory element on the outer label of a medicinal product in the EU?

• Name of the product, strength and pharmaceutical form
• Detailed manufacturing batch production records
• Confidential stability study reports
• Wholesale price list

Correct Answer: Name of the product, strength and pharmaceutical form

Q10. When a manufacturer in the EU proposes a major change to the manufacturing process that affects quality, what regulatory action is typically required?

• Variation application to the competent authority or MA holder
• No action needed if the site is well known
• Only internal memo to production staff
• Immediate suspension of GMP certificate

Correct Answer: Variation application to the competent authority or MA holder

Q11. Annex 16 of EudraLex Volume 4 focuses primarily on which regulatory topic?

• Certification by the Qualified Person and batch release
• Cleaning validation protocols
• Clinical trial labeling
• Packaging artwork copyright

Correct Answer: Certification by the Qualified Person and batch release

Q12. Which practice ensures that packaging components do not adversely interact with the drug product (e.g., leaching, adsorption)?

• Container closure system compatibility testing
• Marketing analysis of label color preferences
• Only visual inspection of packaging
• Batch reconciliation without stability testing

Correct Answer: Container closure system compatibility testing

Q13. Which document must accompany a medicinal product to provide patients with understandable information about safe use in the EU?

• Patient Information Leaflet (PIL)
• Manufacturer’s Annual Report
• Quality Control Laboratory SOP
• Certificate of Analysis for raw materials

Correct Answer: Patient Information Leaflet (PIL)

Q14. Under the Falsified Medicines Directive, what is the “safety feature” composed of?

• Unique identifier (2D barcode) and tamper-evident device
• Only a holographic sticker
• Electronic temperature loggers
• Batch size control stamp

Correct Answer: Unique identifier (2D barcode) and tamper-evident device

Q15. Temperature-sensitive medicinal products require which additional regulatory controls during packaging and distribution?

• Validated cold chain logistics and temperature monitoring
• Only hand-carrying by the manufacturer
• Labeling with manufacturer’s personal email
• No additional controls beyond standard packaging

Correct Answer: Validated cold chain logistics and temperature monitoring

Q16. What is the purpose of a marketing authorisation holder’s (MAH) artwork control process?

• To ensure labeling and carton artwork reflect authorised product information and regulatory compliance
• To minimize the font size to fit more text
• To avoid translation into local languages
• To permit last-minute unapproved changes

Correct Answer: To ensure labeling and carton artwork reflect authorised product information and regulatory compliance

Q17. Which regulatory expectation applies to cleaning validation in a multi-product EU facility?

• Demonstrate acceptable carryover limits and validated cleaning procedures
• Cleaning only when a visual inspection shows dirt
• No cleaning validation if products are similar
• Cleaning validation is optional for sterile products

Correct Answer: Demonstrate acceptable carryover limits and validated cleaning procedures

Q18. If a medicinal product’s PIL requires updating due to new safety information, who is primarily responsible for submitting the update to the competent authority?

• Marketing Authorisation Holder (MAH)
• Any retail pharmacy
• Contract manufacturer only
• Individual prescribing physicians

Correct Answer: Marketing Authorisation Holder (MAH)

Q19. Which practice is essential to ensure correct multilingual labeling across different EU member states?

• Controlled translation process and QA review against the SmPC
• Using machine translation without review
• Translating only the brand name and price
• Relying on distributors to translate labels in the market

Correct Answer: Controlled translation process and QA review against the SmPC

Q20. During EU GMP inspections, which evidence is most persuasive to demonstrate packaging control and security?

• Validated packaging SOPs, batch records, and traceability of packaging components
• A single signed note by the production operator
• Only photographs of finished cartons
• Promises of future improvements without current records

Correct Answer: Validated packaging SOPs, batch records, and traceability of packaging components

Download